CEL-SCI (NYSEAMERICAN:CVM) announced its earnings results on Monday. The company reported ($0.53) EPS for the quarter, Bloomberg Earnings reports. The company had revenue of $0.11 million during the quarter.
Shares of CEL-SCI (NYSEAMERICAN CVM) traded down $0.03 during trading on Tuesday, reaching $1.76. The company had a trading volume of 11,419 shares, compared to its average volume of 271,923. CEL-SCI has a 12 month low of $1.46 and a 12 month high of $4.00. The stock has a market cap of $21.77, a PE ratio of -1.10 and a beta of -1.49.
Separately, Dawson James restated a “neutral” rating on shares of CEL-SCI in a report on Monday, October 16th.
CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines.
Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.